Home > Oncology > Immunotherapy combo fails to improve overall survival in advanced kidney cancer

Immunotherapy combo fails to improve overall survival in advanced kidney cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 27/12/2021 - In previously untreated metastatic renal-cell cancer (mRCC), upfront treatment with the anti-PD-L1 immune-checkpoint inhibitor atezolizumab plus the anti-vascular endothelial growth factor (VEGF) agent bevacizumab did not improve overall survival (OS) compared to standard treatment with sunitinib in the IMmotion151 study. However, findings from an exploratory subanalysis suggest that biomarker analyses may identify patients who could benefit from combined anti-PD-L1 and anti-VEGF therapy, the research team says in JAMA Oncology. In the IMmotion151 study, 915 patients with previously untreated mRCC were randomly assigned to atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) given intravenously every three weeks or oral sunitinib (50 mg/day for four weeks, followed by two weeks off treatment). Patients were stratified by PD-L1 status. At the interim analysis, the atezolizumab/bevacizumab combination had a favorable safety profile ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on